Kidney Transplantation Confers Survival Benefit for Candidates With Pulmonary Hypertension.

UNLABELLED

Kidney transplantation (KT) is controversial in patients with pretransplant pulmonary hypertension (PtPH). We aimed to quantify post-KT graft and patient survival as well as survival benefit in recipients with PtPH.

METHODS

Using UR Renal Data System (2000-2018), we studied 90 819 adult KT recipients. Delayed graft function, death-censored graft failure, and mortality were compared between recipients with and without PtPH using inverse probability weighted logistic and Cox regression. Survival benefit of KT was determined using stochastic matching and stabilized inverse probability treatment Cox regression.

RESULTS

Among 90 819 KT recipients, 2641 (2.9%) had PtPH. PtPH was associated with higher risk of delayed graft function (odds ratio, 1.23; 95% CI, 1.10-1.36;  < 0.01), death-censored graft failure (hazard ratio [HR], 1.23; 95% CI, 1.11-1.38;  < 0.01), and mortality (HR, 1.56; 95% CI, 1.44-1.69;  < 0.01). However, patients with PtPH who received a KT had a 46% reduction in mortality (HR, 0.54; 95% CI, 0.48-0.61;  < 0.01) compared with those who remained on the waitlist.

CONCLUSIONS

Although PtPH is associated with inferior post-KT outcomes, KT is associated with better survival compared with remaining on the waitlist. Therefore, KT is a viable treatment modality for appropriately selected patients with PtPH.